{
    "organizations": [],
    "uuid": "2d0aeda2b0ad07ef884373ca0698072e5c7561da",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-zafgen-to-host-conference-call-to-discuss-first-quarter-2018-financial-results.html",
    "ord_in_thread": 0,
    "title": "Zafgen to Host Conference Call to Discuss Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its first quarter ended March 31, 2018.\nParticipants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations . A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.\nAbout Zafgen\nZafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The companyâ€™s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com .\nMedia/Investor Relations Contacts :\nZafgen, Inc.\nPatricia Allen\nChief Financial Officer\n617-648-9792\nMedia\nKrystle Gibbs\nTen Bridge Communications\nkrystle@tenbridgecommunications.com\n508-479-6358\nInvestors\nJohn Woolford\nWestwicke Partners\nJohn.woolford@westwicke.com\n443-213-0506\nSource:Zafgen, Inc.",
    "published": "2018-05-02T00:30:00.000+03:00",
    "crawled": "2018-05-02T02:49:46.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "boston",
        "may",
        "globe",
        "newswire",
        "zafgen",
        "nasdaq",
        "zfgn",
        "biopharmaceutical",
        "company",
        "leveraging",
        "proprietary",
        "knowledge",
        "metap2",
        "system",
        "biology",
        "develop",
        "novel",
        "therapy",
        "patient",
        "affected",
        "range",
        "metabolic",
        "disease",
        "announced",
        "today",
        "host",
        "conference",
        "call",
        "tuesday",
        "may",
        "et",
        "discus",
        "first",
        "quarter",
        "ended",
        "march",
        "participant",
        "may",
        "access",
        "call",
        "dialing",
        "outside",
        "referencing",
        "conference",
        "id",
        "number",
        "call",
        "also",
        "webcast",
        "live",
        "company",
        "website",
        "http",
        "replay",
        "conference",
        "call",
        "available",
        "beginning",
        "et",
        "may",
        "may",
        "dialing",
        "outside",
        "access",
        "replay",
        "please",
        "provide",
        "conference",
        "id",
        "number",
        "zafgen",
        "zafgen",
        "nasdaq",
        "zfgn",
        "biopharmaceutical",
        "company",
        "leveraging",
        "proprietary",
        "knowledge",
        "metap2",
        "system",
        "biology",
        "develop",
        "novel",
        "therapy",
        "patient",
        "affected",
        "range",
        "complex",
        "metabolic",
        "disease",
        "zafgen",
        "pioneered",
        "study",
        "metap2",
        "inhibitor",
        "common",
        "rare",
        "metabolic",
        "disorder",
        "current",
        "disease",
        "area",
        "focus",
        "type",
        "diabetes",
        "syndrome",
        "liver",
        "disease",
        "company",
        "lead",
        "product",
        "candidate",
        "metap2",
        "inhibitor",
        "phase",
        "clinical",
        "development",
        "unique",
        "property",
        "maximize",
        "impact",
        "metabolic",
        "parameter",
        "relevant",
        "treatment",
        "type",
        "diabetes",
        "related",
        "metabolic",
        "disorder",
        "zafgen",
        "plan",
        "file",
        "investigational",
        "new",
        "drug",
        "ind",
        "application",
        "fda",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "new",
        "molecule",
        "treatment",
        "syndrome",
        "potential",
        "rare",
        "serious",
        "form",
        "obesity",
        "learn",
        "relation",
        "contact",
        "zafgen",
        "patricia",
        "allen",
        "chief",
        "financial",
        "officer",
        "medium",
        "krystle",
        "gibbs",
        "ten",
        "bridge",
        "communication",
        "krystle",
        "investor",
        "john",
        "woolford",
        "westwicke",
        "partner",
        "source",
        "zafgen",
        "inc"
    ]
}